Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04112641 · ClinicalTrials.gov registry record · Phase 2
NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy
A Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, sponsored by Donna Hammond, PhD.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT04112641 is a Phase 2 study of Chemotherapy-induced Peripheral Neuropathy that is active but no longer recruiting, run by Donna Hammond, PhD. The registered enrollment target is 48 participants, below the 137-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04112641, a Phase 2 study of Chemotherapy-induced Peripheral Neuropathy, is active but no longer recruiting, sponsored by Donna Hammond, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this randomized, double-blind, placebo-controlled, parallel group phase II trial is to determine whether nicotinamide riboside (NIAGEN®, NR) can ameliorate persistent peripheral neuropathy in cancer survivors who have completed chemotherapy with taxane or platinum-complex compounds between 1 and 12 months earlier.
Conditions Studied
Interventions
- DRUG Placebo capsules
- DRUG Nicotinamide riboside
Study Locations (1)
Iowa
- Donna Hammond - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04112641
The ClinicalTrials.gov registry entry for NCT04112641 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 29 other Chemotherapy-induced Peripheral Neuropathy trials with a reported enrollment target (65% lower). The listed sponsor is Donna Hammond, PhD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chemotherapy-induced Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo capsules is the first listed.
NCT04112641 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT04112641 about?
NCT04112641 is a clinical study titled "NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy". The purpose of this randomized, double-blind, placebo-controlled, parallel group phase II trial is to determine whether nicotinamide riboside (NIAGEN®, NR) can ameliorate persistent peripheral neuropathy in cancer survivors who have completed chemotherapy with taxane or platinum-complex compounds be...
What is the current status of trial NCT04112641?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-02-19. Estimated completion is 2026-07-01.
What conditions does trial NCT04112641 study?
This clinical trial studies the following conditions: Chemotherapy-induced Peripheral Neuropathy.
What interventions are being tested in trial NCT04112641?
The interventions under investigation include: Placebo capsules (DRUG), Nicotinamide riboside (DRUG).
Who is sponsoring clinical trial NCT04112641?
This trial is sponsored by Donna Hammond, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04112641 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chemotherapy-induced Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
RECRUITING · Phase 2
-
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
RECRUITING · Phase 2
-
A Study of Topical Pirenzepine or Placebo in Oncology Patients With Chemotherapy Induced Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)
ACTIVE NOT RECRUITING · Phase 2
-
PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.